BRAF Inhibitor PLX8394

An orally bioavailable inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential antineoplastic activity. BRAF inhibitor PLX8394 appears to selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, which may subsequently inhibit the proliferation of tumor cells which express mutated forms of BRAF. This inhibitor appears to be effective against tumors that express multiple mutated forms of the kinase and may be an effective therapeutic agent for tumors that are resistant to other BRAF inhibitor therapies that are specific for the BRAF V600E mutant. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAP kinase/ERK signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms of BRAF are associated with a number of neoplastic diseases. (NCI Thesaurus)

YOU MAY ALSO LIKE

BRAF Inhibitor ARQ 736

An orally bioavailable, highly soluble phosphate prodrug of B-raf (BRAF) protein kinase with potential antineoplastic activity. BRAF inhibitor ARQ 736 is converted…

BRAF gene

A gene that makes a protein called B-RAF, which is involved in sending signals in cells and in cell growth. This gene…

BRAF (V600E) mutation

A specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in…

BRAF (V600E) kinase inhibitor RO5185426

A drug used to treat advanced melanoma that has a mutated (changed) form of a cell protein called BRAF. It is…

Bradypnea

Abnormal decrease of rate of breathing.

Bradykinin Receptor B2

Bradykinin receptor B2 protein (391 aa, 44 kD) is a cell communication process protein that is encoded by the BDKRB2 gene and…